Management Team

Mr Antosik has over 25 years management experience in the pharmaceutical industry. Previous positions include Deputy Managing Director of Syntex Ireland and Managing Director of Angus Fine Chemicals. In these roles he was responsible for all site functions including manufacturing, engineering, quality and project management.

Prior to joining GW, Mr Antosik was Production Director with Scotia Pharmaceuticals Ltd and was responsible for the successful regulatory manufacturing submission in both the USA and Europe for Scotia's most important oncology drug. Also at Scotia, he managed the drug substance technology transfer, plant build, commissioning and process scale-up. This plant passed a pre-approval inspection by the FDA.

Mrs Emery has over 25 years management experience in the pharmaceutical and related industries, including both large multinational organisations and small entrepreneurial companies. Before working with GW, Mrs Emery was Group Quality Assurance Manager with Scotia Holdings PLC, where she was responsible for the creation and management of quality systems, that were involved in inspections and approval by both US and UK Regulatory Authorities. Prior to that she was Technical Affairs Manager for Sterling-Winthrop, now Sanofi-Synthelabo, where she was responsible for a variety of technical projects, including preparation of drug master files and Regulatory support.

Mrs Emery has particular experience with other natural products developed for use as pharmaceuticals, acting as the Expert in European regulatory dossiers. She has also been involved in technical transfer of product from R & D through to commercial manufacturing and distribution.

Mrs Emery is a Qualified Person, a Fellow of the Royal Society of Chemistry and a member of TOPRA (The Organisation for Professionals in Regulatory Affairs)

Dr Gibson more than 25 years experience in pharmaceutical development, working with new chemical entities and generic products, in both contract research and established pharmaceutical companies.

Prior to joining GW Pharmaceuticals Dr Gibson was Director of Scientific Services for Elan Transdermal Technologies (UK) Limited (previously Ethical Pharmaceuticals Ltd) and was responsible for a wide range of technical and scientific activities for the company, including formulation development, analytical services, bioanalysis and information technology services.

Dr Gibson was co-founder of Bioanalytical Research Ltd in 1985, a contract research company specialising in bioanalysis for the pharmaceutical industry, which was sold in 1990 to Ethical Pharmaceuticals Ltd.

Ms Mead is an attorney specialising in health care law. For eleven years prior to joining GW, she served as Legal Counsel to the California Medical Association, the largest state medical association in the United States. During that time, she has developed special expertise in the legal and regulatory issues surrounding the production of medicinal cannabis. She has also prepared detailed guidelines on the subject for the medical profession, which have been widely adopted throughout that State and the US generally.

Prior to joining the California Medical Association, Ms Mead served as a litigator for Morrison & Foerster and was previously a law professor at Arizona State University College of Law.

Professor Pertwee joined GW as Director of Pharmacology in March 2002, and at the same time has retained his position as Professor of Neuropharmacology at the University of Aberdeen. He is one of the world's leading cannabinoid scientists, having researched this area for over 30 years, and is the author of over 240 publications. He is frequently consulted on the therapeutic potential of cannabis and cannabinoids by parliamentary committees and leading medical organisations and has been involved with both the 1998/99 Royal Pharmaceutical Society working party on cannabis and the House of Lords Science & Technology Committee investigation into cannabis.

Professor Pertwee is also Co-chair of the International Union of Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors and has also previously held the positions of President and International Secretary for the International Cannabinoid Research Society (ICRS).

Before joining GW as its first employee in 1998, Dr Potter had twenty three years research experience as a horticulturalist and agronomist. He also managed security at the research laboratory complex of a multinational company for three years.

Dr Potter gained his research PhD in 2009 at Kings College London, having studied the pharmacognosy of Cannabis sativa. He is a Chartered Biologist, a Fellow of the Linnean Society and a Chartered Member of the Institute of Occupational Safety and Health.

Dr Potter regularly acts as an expert witness and police advisor on cannabis issues and, in recognition of this service, he received a commendation from ACPO (The Association of Chief Police Officers) in 2007 and 2009.

Mr Potts has been with GW Pharmaceuticals since 2001 and has worked in the pharmaceutical industry for over 13 years. Prior to joining GW, Mr Potts worked for Astra Zeneca in Sweden and then for Napp Pharmaceuticals in the UK as a Clinical Research Scientist where his principal responsibilities and achievements included the conception, design and execution of Phase II, III and IV Pan European clinical studies, investigating schedule II controlled drug substances.

Over the past 5 years, Mr Potts has successfully expanded GW Pharmaceuticals’ clinical operations into Mainland Europe, Eastern Europe, Canada and the USA. He has disease area experience in Pain, (neuropathic, inflammatory and nociceptive), Multiple Sclerosis, Asthma and Hypertension.

Mr Putt has over 15 years operations management experience in the FMCG and pharmaceutical industries. His career started in manufacturing with Kraft Jacob Suchard before moving to Cadbury Schweppes where he made the transition from Production Management to Supply Chain Management and became responsible for the planning function.

More recently he was Materials Manager for Abbott Laboratories UK where his responsibilities covered New Product Introduction, Demand Management, Planning, Purchasing and Distribution/Warehousing.

Mr Putt joined GW in 2003 and is responsible for commercial Sativex supplies, supply of named patient prescriptions around the world, and international clinical trials.

Dr Robson is an expert in the therapeutic potential of cannabis and cannabinoids. In 1996 he was commissioned by the Department of Health to carry out a critical review of the relevant scientific literature and in 1998 was called on to submit both written and verbal evidence to the House of Lords Science & Technology Committee investigation into cannabis.

Prior to joining the Group, Dr Robson was for the previous ten years, a Consultant Psychiatrist in Oxford and Senior Clinical Lecturer in the Oxford University Department of Psychiatry. In addition to his duties as Director of the Cannabinoid Research Institute, Dr Robson retains the position of Senior Research Fellow in the Oxford University Department of Psychiatry.

Prior to taking up his psychiatry posts at Oxford, Dr Robson worked for eight years within the pharmaceutical industry, initially as a clinical pharmacologist and then as Director of Clinical Research at Wyeth Laboratories.

Mr Stott has been with GW since January 2001 and has twenty-two years experience in the pharmaceutical industry covering a wide range of new chemical entities, biotechnology products and plant-based medicines, with 20 years experience of clinical development and 14 years experience of preclinical development.

Prior to joining GW, Mr Stott was Clinical Programme Manager & International Project Leader at Napp Pharmaceuticals Ltd, leading an international joint development programme of a plant-based medicine. Prior to this he was Clinical Projects Manager at the plant medicines company Phytopharm plc between 1996 and 1999, managing clinical and pre-clinical development programmes. Mr Stott also has experience gained at Astra Zeneca, Schering-Plough Limited, Genzyme (UK) Limited and Alpha Therapeutics Limited (now Grupo Grifols).

Mrs Thompson has been with GW since 1999 and has worked in the field of management of regulatory affairs for over 14 years. Before joining GW she worked at Novartis as Manager, Regulatory Affairs, in the veterinary products division. Prior to entering the life sciences industry, Mrs Thompson worked for 10 years in the agricultural arena, including chairing working parties in Brussels and London involved in feed additive legislation.